– CANADA, Calgary – Oncolytics Biotech Inc. (TSX: ONC / NASDAQ: ONCY), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Pat Andrews to its Board of Directors.
About Patricia S. Andrews
Ms. Andrews is an accomplished biopharmaceutical executive and public company board member with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercialization, and business development. Ms. Andrews currently serves as a Director and Member of the Audit Committee at GlycoMimetics. During her tenure, the company planned and initiated its first Phase 3 study and is preparing for commercialization.
Ms. Andrews previously served as CEO of Sumitomo Pharma Oncology, Inc., where she led the organization through the integration of its multiple predecessor companies. Under her leadership, the organization completed three Phase 3 trials and expanded the clinical pipeline from two programs to eight. Before SMP Oncology, Ms. Andrews served as CCO for Incyte and led the organization through the launch preparations and introduction of Jakafi, the company’s first commercial product, a novel, first-in-class, first-in-disease agent for the treatment of myelofibrosis. While with Incyte, she also steered landmark licensing arrangements with Novartis and Eli Lilly that were critically important to fund the company’s long-term trajectory.
Before Incyte, Ms. Andrews spent 17 years with Pfizer, ultimately serving as VP and GM of the U.S. Oncology Business Unit, a $900 million portfolio at the time. Under her leadership, Sutent was launched, becoming the market leader in renal cell carcinoma, and a refreshed positioning of Camptosar led to robust revenue growth after years of declining sales in colorectal cancer. Ms. Andrews is a member of the Boston chapter of the Board of Advisors for Life Science Cares, a collective impact organization dedicated to fighting poverty in local communities.
She earned an MBA from the University of Michigan and her BA from Brown University.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances toward registrational studies in metastatic breast cancer and pancreatic cancer.
For more information: https://www.oncolyticsbiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
